PRESS RELEASES

Date	Title
Sep 3, 2019	Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Sep 2, 2019	Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Aug 9, 2019	Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
May 30, 2019	Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
May 7, 2019	Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Mar 14, 2019	Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Mar 7, 2019	Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Mar 6, 2019	Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Feb 21, 2019	Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
Feb 7, 2019	Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com